Information about Evista (Raloxifene)
Evista (raloxifene) is a medication mainly prescribed for the prevention and treatment of osteoporosis in postmenopausal women. It is part of a drug class called selective estrogen receptor modulators (SERMs). Evista mimics the effects of estrogen on bone tissue, increasing bone density and reducing the risk of fractures. It is also prescribed to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis or those at high risk of developing breast cancer.
Product Highlights
- Evista is primarily used to prevent and treat osteoporosis in postmenopausal women by increasing bone density and reducing the risk of fractures.
- It is also indicated to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of developing the disease.
Key Ingredient
Key Benefits
- Evista helps prevent bone loss in postmenopausal women, improving bone density and reducing the risk of fractures due to osteoporosis.
- It has been shown to lower the risk of invasive breast cancer in postmenopausal women at high risk.
- Unlike traditional hormone replacement therapy (HRT), Evista does not contain estrogen but mimics its effects on bones, making it an option for women who cannot take estrogen therapy.
- Evista may have a protective effect on cholesterol levels, contributing to cardiovascular health.
Direction of Use
- Evista is taken once daily, typically with or without food. It is important to take it consistently at the same time each day to maximize its effectiveness.
- The length of treatment will depend on the condition being treated. For osteoporosis, long-term use may be recommended, while for breast cancer risk reduction, treatment duration will depend on individual patient needs and healthcare provider recommendations.
- When taking Evista for osteoporosis, it is important to ensure adequate calcium and vitamin D intake, either through diet or supplements, to support bone health.
Safety Concerns
- Evista can increase the risk of blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. Women with a history of blood clots or other thromboembolic disorders should avoid using Evista.
- A common side effect of Evista is hot flashes, similar to symptoms of menopause.
- While Evista does not appear to increase the risk of endometrial cancer, it is still important to monitor for any unusual vaginal bleeding or other changes in reproductive health.
- Evista should be used with caution in individuals with liver disease. Regular liver function tests may be required during treatment.
- Although Evista helps prevent fractures due to osteoporosis, it is important to address any potential falls or accidents, as bone density improvement may take time.
Avoid Evista (Raloxifene) If
- Evista should be avoided in women who have a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or a stroke, as it can increase the risk of blood clots.
- Evista should not be used during pregnancy or breastfeeding, as it can harm a fetus or pass into breast milk.
- Evista should be avoided in women with severe liver impairment or active liver disease, as it can affect liver function.
- If you are allergic to raloxifene or any of the ingredients in Evista, you should not take the medication.
